Cancer Immunotherapy Market Scenario, Leading Players, Segments Analysis and Growth Drivers to 2023

The Global Cancer Immunotherapy Market was USD 36.8 billion in 2016 which is expected to grow at a healthy CAGR of 14.8% and reach till USD 101.6 billion by 2023.

Global cancer immunotherapy market has been growing at an impressive rate in recent years and will maintain the same in coming future. Approximately 100 different types of cancer have been identified. Cancer is condition of uncontrolled cell growth. Cancer Immunotherapy, on the other hand, helps the immune system to target cancerous tumor cells, which is in fact the natural tendency of the body but tends to weaken with the advent of disease infections. According to W.H.O. cancer is the leading cause of the total number of deaths globally in 2015, and was responsible for 8.8 million deaths in 2015. Statistics suggest that nearly 1 in 6 patients die due to cancer. Due to deteriorating lifestyle, smoking, and alcoholism are responsible for increasing the incidence of cancer. Increasing cancer population is the major reason for increasing the global immunotherapy market. Many therapies are available in the market but the advantage of immunotherapy is its high effectiveness and less side effects as compared to other therapies. This therapy is effective for patients suffering from melanoma cancer when chemotherapy and other radiation therapies do not work.

The respective statistics of deaths occurring due to lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer were recorded to be found as 16,90,000, 788,000, 774,000, 754,000, and 571,000 respectively, in 2015

Get a Sample Copy of This Report @ https://www.marketresearchfuture.com/sample_request/567 .

Most common cancers are lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer, which have been recorded to cause 1.69 million, 788,000, 774 thousands, 754 thousands, and 571 thousands deaths respectively in year 2015.

According to CDC, more than 1.5 million people are diagnosed with cancer every year in the U.S., and more than 5 lakhs people are not able to survive. Reports show that 50 % of the total deaths could be prevented through making a healthy choice. Smoking is the leading cause of lung cancer, which is responsible for 90 % of the total deaths in men and 80% in women.

Key Players:

Hoffmann-La Roche AG, Merck & Co., Inc., Novartis AG, GlaxoSmithKline Plc., Amgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Celgene Corporation, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc. are some of the leading players at the cutting edge of the competition in the market of cancer immunotherapy across the globe.

Key Developments:

Key players in the market are engaged in the development of new products to capture the market globally. Therefore, key market players are investing more in research and development activity, in order to lead the global market. In this regards, market players undertake various strategic approaches.

Get Attractive Discount on This Report @ https://www.marketresearchfuture.com/check-discount/567 .

Pfizer Inc.

Pfizer Inc. is a major research based bio pharmaceutical organization. The company manufactures medicines and vaccines that help individuals in their disease condition and keep them from becoming sick in any case.

In August, 2016, the company announced the approval of FDA approval TROXYCA ER extended-release capsules CII for pain management. The drug is used for abuse-deterrent properties for the management of pain and will help Pfizer to improve their goodwill and sales with this new product

In July 2016, Bind Therapeutics entered in an asset purchase agreement with Pfizer Inc. Bind Therapeutics Inc. entered into an asset purchase agreement with Pfizer, Inc. On July 26, 2016, company amended the stalking horse agreement. The acquisition is expected to close on or about August 1, 2016.

Segmentation

The global cancer immunotherapy market is segmented on the basis of therapy types, by application, by end user.

On the basis of type, it is segmented into monoclonal antibodies, adoptive cell transfer, cytokines, treatment vaccines, bacillus calmette-guérin, and others. Monoclonal antibodies further segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, and bispecific monoclonal antibodies. Cytokines are further segmented into Interferon, Interleukins. On the basis of application, it is segmented into liver cancer, childhood cancer, colorectal cancer, stomach cancer, lung cancer and others. On the basis of end user, it is segmented into hospitals, clinics, and others.

…Continued

Inquire about This Report @ https://www.marketresearchfuture.com/enquiry/567 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.